Similar articles

• Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy.

  Page NA, Schroeder WS. Page NA, et al. Ann Pharmacother. 2007 Jan;41(1):61-7. doi: 10.1345/aph.1H437. Epub 2007 Jan 2. Ann Pharmacother. 2007. PMID: 17200429 Review.
• An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.

  Shaker M, Lobb A, Jenkins P, O'Rourke D, Takemoto SK, Sheth S, Burroughs T, Dykewicz MS. Shaker M, et al. J Allergy Clin Immunol. 2008 Jan;121(1):81-7. doi: 10.1016/j.jaci.2007.06.047. Epub 2007 Aug 22. J Allergy Clin Immunol. 2008. PMID: 17716716
• Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.

  Bhatt DL. Bhatt DL. Am J Cardiol. 2009 Feb 2;103(3 Suppl):11A-19A. doi: 10.1016/j.amjcard.2008.11.018. Am J Cardiol. 2009. PMID: 19166708 Review.
• An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.

  Terpening C. Terpening C. J Am Board Fam Med. 2009 Jan-Feb;22(1):51-6. doi: 10.3122/jabfm.2009.01.070282. J Am Board Fam Med. 2009. PMID: 19124633 Review.
• Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.

  van Werkum JW, Topcu Y, Postma S, Kelder JC, Hackeng CM, ten Berg JM, Verheugt FW. van Werkum JW, et al. Thromb Haemost. 2008 Mar;99(3):637-9. doi: 10.1160/TH07-07-0465. Thromb Haemost. 2008. PMID: 18327417 No abstract available.